Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology News
  • Novel triple-drug FDC...

Novel triple-drug FDC superior to dual combination in type 2 diabetes patients poorly controlled with metformin

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2 Jun 2023 6:00 AM  |  Updated On 2 Jun 2023 11:03 AM
Novel triple-drug FDC superior to dual combination in type 2 diabetes patients poorly controlled with metformin
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

India: A recent study has shown a triple-drug fixed-dose combination (FDC) of sitagliptin + dapagliflozin + metformin ER to be superior to dual combinations in terms of HbA1c reduction in patients with type 2 diabetes poorly controlled with metformin.

"Our findings provide evidence for considering triple FDC of dapagliflozin + sitagliptin + metformin ER as an alternative option with minimal risk of weight gain and hypoglycemia while considering oral triple-combination therapy for patients to achieve their glycemic target," the researchers wrote in their study published in Advances in Therapy.

Type 2 diabetes is a progressive disease in which microvascular and macrovascular complications and mortality risks are strongly associated with hyperglycemia. Achieving glycemic control remains the treatment's primary goal to prevent these complications. Estimates in 2019 revealed that 77 million people had diabetes in India, which is expected to increase to over 134 million by 2045. Considering the disease's progressive nature, many guidelines recommend dual or triple drug therapy based on HbA1c (glycated haemoglobin) level.

Using FDC helps in improving therapy compliance and can provide optimum therapeutic benefits. Mechanisms of action of sodium–glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase 4 (DPP4) inhibitors are complementary to metformin with low hypoglycemia risk. Studies have shown the beneficial effects of adding both SGLT2 inhibitors and DPP4 inhibitors after metformin monotherapy.

Rakesh K. Sahay, Osmania General Hospital, Hyderabad, India, and colleagues aimed to compare the safety and efficacy of triple-drug FDC of sitagliptin (SITA) + dapagliflozin (DAPA) + metformin (MET) extended-release (ER) with DAPA + MET ER and h SITA + MET sustained release (SR) in type 2 diabetes patients poorly controlled with metformin in phase 3, randomized, open-label, active-controlled study.

The study included patients with HbA1c ≥ 8% (64 mmol/mol) and ≤ 11% (97 mmol/mol). They were randomized in the ratio of 1:1:1 to receive either once-daily FDC of DAPA + SITA + MET ER (10 mg + 100 mg + 1000 mg) tablets (n = 137) or co-administration of SITA + MET SR (100 mg + 1000 mg) tablets once daily (n = 139) or FDC of DAPA + MET ER (10 mg + 1000 mg) tablets once daily (n = 139). The primary endpoint was a mean change in HbA1c from baseline to week 16.

The authors reported the following findings:

  • The mean baseline HbA1c was approximately 9% (75 mmol/mol) in each treatment group.
  • At week 16, the adjusted mean reduction in HbA1c from baseline was significantly more significant with DAPA + SITA + MET ER (− 1.73%) compared to SITA + MET SR (− 1.28%) and DAPA + MET ER (− 1.33%; difference − 0.4%).
  • At week 12, the reduction in HbA1c from baseline was significantly more significant with DAPA + SITA + MET ER compared to SITA + MET SR and DAPA + MET ER.
  • At week 16, DAPA + SITA + MET ER showed a significant reduction in postprandial blood glucose compared to DAPA + MET ER and a significant decrease in fasting blood glucose with DAPA + SITA + MET ER compared to SITA + MET SR.
  • The proportion of patients achieving HbA1c < 7.0% at week 16 was significantly higher with DAPA + SITA + MET ER (38.5%) versus SITA + MET SR (12.8%) and DAPA + MET ER (21.3%). All study medications were well tolerated.

"Triple FDC of once daily DAPA + SITA + MET ER tablets was significantly better in achieving glycemic control than dual combination once daily in type 2 diabetes patients poorly controlled with metformin without any significant safety concerns," the researchers concluded.

Reference:

Sahay, R.K., Giri, R., Shembalkar, J.V. et al. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations. Adv Ther (2023). https://doi.org/10.1007/s12325-023-02523-z

Advances in Therapysitagliptindapagliflozinmetformintype 2 diabetesDPP4 inhibitorFixed-dose combinationSGLT2 inhibitor
Source : Advances in Therapy
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    View All

    Journal Club Today

    Is Fitness Overrated? Study Questions the True Impact of Fitness on Early Death

    Is Fitness Overrated? Study Questions the True Impact of Fitness on Early Death

    View All

    Health News Today

    Health Bulletin 17/ May/ 2025

    Health Bulletin 17/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok